Ibritumomab tiuxetan (Zevalin) followed by high-dose chemotherapy and autologous stem-cell transplantation results in improved survival of patients with chemo-refractory non-Hodgkin's lymphoma expected to have poor outcome with standard pre-transplant conditioning.

被引：1
|
作者：
Shimoni, Avichai [1 ]
Zwass, Tsila [1 ]
Oksman, Yaacov [1 ]
Hardan, Izhar [1 ]
Shem-Tov, Noga [1 ]
Yerushalmi, Ronit [1 ]
Avigdor, Abraham [1 ]
Ben-Bassat, Isaac [1 ]
Nagler, Arnon [1 ]
机构：
[1] Chaim Sheba Med Ctr, Dept Nucl Med, Div Hematol Bone Marrow Transplantat, IL-52621 Tel Hashomer, Israel
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3052.3052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3052
引用
收藏
页码：869A / 869A
页数：1
相关论文
共 50 条
  • [1] Ibritumomab tiuxetan combined with high-dose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemo-refractory aggressive non-Hodgkin's lymphoma.
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Nagler, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [2] Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma
    Shimoni, Avichai
    Zwas, S. Tzila
    Oksman, Yakov
    Hardan, Izhar
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Avigdor, Abraham
    Ben-Bassat, Isaac
    Nagler, Arnon
    EXPERIMENTAL HEMATOLOGY, 2007, 35 (04) : 534 - 540
  • [3] Yttrium-90 -: ibritumomab tiuxetan (Zevalin®) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S145 - S145
  • [4] Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma
    Shimoni, A.
    Zwas, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S93 - S93
  • [5] Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation (SCT) in patients with chemo-refractory now Hodgkin's lymphoma
    Shimoni, A
    Zwass, T
    Oksman, Y
    Hardan, L
    Shem-Tov, N
    Yershalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (02) : 119 - 119
  • [6] Ibriturnomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma.
    Shimoni, A
    Zwas, T
    Oksman, Y
    Hardan, I
    Shem-Tov, N
    Yerushalmi, R
    Avigdor, A
    Ben-Bassat, I
    Nagler, A
    BLOOD, 2005, 106 (11) : 329A - 329A
  • [7] Ibritumomab tiuxetan (Zevalin) combined with highdose chemotherapy and autologous stem-cell transplantation (SCT) in patients with chemorefractory aggressive non-Hodgkin's lymphoma
    Shimoni, A.
    Zwass, T.
    Oksman, Y.
    Hardan, I.
    Shem-Tov, N.
    Yerushalmi, R.
    Avigdor, A.
    Ben-Bassat, I.
    Nagler, A.
    EXPERIMENTAL HEMATOLOGY, 2006, 34 (09) : 64 - 64
  • [8] High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma
    Provencio, Mariano
    Fayad, Luis E.
    MEDICINA CLINICA, 2008, 130 (02): : 60 - 65
  • [9] Ibritumomab tiuxetan (Zevalin) and BEAM chemotherapy as conditioning regimen for autologous stem cell transplantation in resistant/relapsed non-Hodgkin lymphoma patients: evaluation of toxicity and efficacy
    Labrador, M.
    Buenasmananas, D.
    Martinez, M. C.
    Fernandez, N.
    Gomez, L. M.
    Garcia, E.
    Martin, C.
    Rodriguez, G.
    Rojas, R.
    Benitez, A.
    Vallejo, J. A.
    Martinez, F.
    Torres, A.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S455 - S455
  • [10] Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma
    A Shimoni
    S T Zwas
    Y Oksman
    I Hardan
    N Shem-Tov
    A Rand
    R Yerushalmi
    A Avigdor
    I Ben-Bassat
    A Nagler
    Bone Marrow Transplantation, 2008, 41 : 355 - 361
12345